American Airlines Pilots First to Use CEFA Aviation Flight Replay App in the U.S.
American Airlines, the world’s largest airline, is the first carrier in the U.S. to adopt CEFA AMS, an Electronic Flight Bag (EFB) application allowing pilots to virtually review flight data on their tablet after landing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005055/en/
CEFA AMS (Aviation Mobile Services) is the first self-improvement tool allowing individual pilots to access and review the specifics of their flight after landing. (Photo: Business Wire)
CEFA AMS (Aviation Mobile Services) is the first self-improvement tool allowing individual pilots to access and review the specifics of their flight after landing.
Captain Neil Raaz, Operations Safety Director at American Airlines, says that CEFA AMS is the next step in American’s data-driven approach to relentlessly advance safety. “By choosing CEFA AMS, we are now able to advance the Safety-II approach in a practical way in our operations. This progressive new debriefing capability will help promote a culture of continuous self-improvement and reinforce American’s safety-first mentality into each and every flight.”
“We are delighted to partner with American Airlines, who sets the standard when it comes to flight safety,” says Dominique Mineo, CEO of CEFA Aviation , a France-based software company specialized in flight safety and pilot training. “Being able to deploy our innovation in the U.S. was one of our main ambitions. Today we have the opportunity to work with an airline committed to the highest safety standards and, beyond the conventional safety approach, aiming for Safety-II implementation.” Mineo added.
The implementation of CEFA Aviation’s EFB flight replay capability is a milestone for American. It demonstrates its will for innovation as well as a strong desire to lead the shift in pilot empowerment through increased access to and awareness of operational flight data.
This new partnership between CEFA and American Airlines will create an entirely new and revolutionary approach to proactive safety in airline operations and clearly demonstrates both organization’s commitment to being industry leaders in aviation safety.
About CEFA Aviation
CEFA Aviation, a privately held French company, enhances pilot training and flight safety, developing world-leading 3D animation software and services for the past 20 years. The innovative solutions developed by its experts recreate flights with high details and accuracy based on data from aircraft flight recorders.
More than 100 major and regional airlines, cargo operators, and investigative authorities on five continents are using the company’s core software, CEFA FAS (Flight Animation System), for pilot training and safety analysis.
Translating flight data into precise visualization requires an in-depth understanding of the complexity of aircraft systems and software engineering. CEFA Aviation has been a pioneer in easy-to-use flight data animation since Dominique Mineo founded the company in 2000. Its long-lasting success is attributable to a passion for aviation and innovation, listening to its clients, and delivering gold-standard support. CEFA Aviation is headquartered in the Alsace region of France.
At the Dubai Airshow 2017, CEFA Aviation unveiled a new breakthrough visualization tool to enhance further and personalize pilot training: CEFA AMS. Additional information can be found at www.cefa-aviation.com
Join us on social media and never miss a press release on Twitter @CEFAAviation and LinkedIn at www.linkedin.com/company/cefa-aviation
About American Airlines Group
American’s purpose is to care for people on life’s journey. Shares of American Airlines Group Inc. trade on Nasdaq under the ticker symbol AAL and the company’s stock is included in the S&P 500. Learn more about what’s happening at American by visiting news.aa.com and connect with American on Twitter @AmericanAir and at Facebook.com/AmericanAirlines.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005055/en/
Contact information
CEFA Aviation
Paulina Calderon
communication@cefa-aviation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom